about
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsRepeated observation of breast tumor subtypes in independent gene expression data setsClinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionDNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancersGlomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancerAbsence of p21 expression is associated with abnormal p53 in human breast carcinomas.Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.Alternative splicing and mutation status of CHEK2 in stage III breast cancer.Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.ABCB1 and GST polymorphisms associated with TP53 status in breast cancerSpecific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsEffects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependencyPrimary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcomeDifferential effect of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients
P50
Q27860709-3636C813-D3E2-4A7D-9BFB-3D97D75A9C19Q28131820-861C557C-C2AF-4260-96F7-36241B5697FBQ28728389-61B09A88-8013-4BFE-A256-81213E2F346AQ33816178-29C0D9E5-EFF4-4D43-9715-592BCA8E8FD1Q34013967-BC80A3DB-C8B4-4753-824A-9CB97ADC1284Q35108398-F51BA6F2-472F-490F-A775-12F8FC913B15Q36430949-703C954C-ADAA-4FAF-AF50-C03EA87771C1Q36623079-AC6687B3-4658-4C10-8C42-1AAD3EBB59D5Q40907746-353C25D8-3A9B-4559-8702-8D8FCDF48049Q44443788-52A20B2B-1E31-4469-9645-8F5970F32CD3Q44679253-883C4B1E-5F9C-47E9-9192-B62183BAF2B7Q48173616-102F08AC-016E-46CC-934D-90807C3024DEQ52542729-770AD164-A44C-4496-9183-6431C9FDB5E0Q57421083-7333385B-F55F-430A-BBD6-E8CC4C7939A3Q71169983-3254A3EA-0FAD-40C0-82EB-F12DB303AC33Q73112505-E21D5D7E-E2CE-4A3B-9BAA-6F6F7CDDB746Q73322847-17710245-314E-4237-83A1-A7E1B0C9512CQ73372324-E4AAC930-B3C7-425A-ABBB-BBFEF44F5475
P50
description
forsker
@nb
researcher
@en
name
Stephanie Geisler
@da
Stephanie Geisler
@de
Stephanie Geisler
@en
Stephanie Geisler
@es
Stephanie Geisler
@fr
Stephanie Geisler
@nb
Stephanie Geisler
@nl
Stephanie Geisler
@nn
Stephanie Geisler
@sv
type
label
Stephanie Geisler
@da
Stephanie Geisler
@de
Stephanie Geisler
@en
Stephanie Geisler
@es
Stephanie Geisler
@fr
Stephanie Geisler
@nb
Stephanie Geisler
@nl
Stephanie Geisler
@nn
Stephanie Geisler
@sv
prefLabel
Stephanie Geisler
@da
Stephanie Geisler
@de
Stephanie Geisler
@en
Stephanie Geisler
@es
Stephanie Geisler
@fr
Stephanie Geisler
@nb
Stephanie Geisler
@nl
Stephanie Geisler
@nn
Stephanie Geisler
@sv